Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ResMed (RMD)

ResMed reports 11% higher Q3 fiscal 2026 revenue of $1.4 billion; EPS rises 10%

Positive Impact 3 of 5 earnings Written later

ResMed reported results for the quarter ended March 31, 2026, with revenue up 11% to $1.43 billion and GAAP diluted EPS of $2.74, up from $2.48, while non-GAAP diluted EPS rose 21% to $2.86. The company also declared a quarterly cash dividend of $0.60 per share, with a record date of May 14, 2026 and payment on June 18, 2026.

Key points

  • Revenue was $1,431.4 million, up 11% reported and 8% on a constant currency basis; GAAP gross margin rose 290 basis points to 62.2%.
  • GAAP net income was $398.7 million; non-GAAP net income rose 20% to $417.2 million.
  • Operating cash flow was $554 million; the company paid $87 million in dividends and repurchased shares for $175 million in the quarter.
  • Quarterly dividend of $0.60 per share: ex-dividend date May 13, 2026; record date May 14, 2026; payable June 18, 2026.

The filing

CompanyResMed (RMD)
Form8-K, current report
Filed with the SECApr 30, 2026, 4:06 PM ET
Accession number0001193125-26-197192

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.